GE Healthcare’s New Value Proposition: The Strategic Language Of Software
For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.
You may also be interested in...
The goliaths of imaging and in vitro diagnostics have sealed a pact to codevelop a new data analytics platform for faster clinical decision-making, more accurate diagnosis and more personalized treatments.
GE Healthcare’s Life Sciences business continues to build its asset base in the cell and gene therapy sector, and after several strategic M&A deals in recent months is facing 2017 in a confident mood, according to Phil Vanek, cell therapy growth leader.
In this installment of VC Playbook, profiling venture capital strategies in biopharma and medtech, In Vivo talks to Sofinnova Partners' Graziano Seghezzi about market access trends, Italy’s growing biotech offering and the perils of “health nationalism” to business partnering in the aftermath of COVID-19.